ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 07:41:09 pm | |||
| 724.9 USD | -1.00% |
|
727.3 | +0.33% |
| Apr. 25 | Scholz pledges further support for the pharmaceutical industry | DP |
| Apr. 25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
Financials (USD)
| Sales 2024 * | 41.36B | Sales 2025 * | 51.28B | Capitalization | 653B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.86B | Net income 2025 * | 15.78B | EV / Sales 2024 * | 16.2 x |
| Net Debt 2024 * | 15.19B | Net Debt 2025 * | 10.74B | EV / Sales 2025 * | 12.9 x |
| P/E ratio 2024 * |
59.8
x | P/E ratio 2025 * |
40.4
x | Employees | 43,000 |
| Yield 2024 * |
0.71% | Yield 2025 * |
0.82% | Free-Float | 99.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
| 1 day | +0.33% | ||
| 1 week | -2.83% | ||
| Current month | -6.82% | ||
| 1 month | -6.24% | ||
| 3 months | +15.50% | ||
| 6 months | +23.60% | ||
| Current year | +24.35% |
1 week
718.30
752.64
1 month
718.30793.67
Current year
579.05800.78
1 year
380.77800.78
3 years
178.58800.78
5 years
101.36800.78
10 years
57.81800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +3.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 724.9 | -1.00% | 2,608,752 |
| 24-04-24 | 732.2 | -1.81% | 2,133,427 |
| 24-04-23 | 745.7 | +1.96% | 2,042,029 |
| 24-04-22 | 731.3 | +0.69% | 2,354,096 |
| 24-04-19 | 726.3 | -2.63% | 3,505,526 |
Delayed Quote Nyse, April 25, 2024 at 04:00 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
724.9
USD
Average target price
813.3
USD
Spread / Average Target
+12.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.35% | 653B | |
| +25.13% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.49% | 233B | |
| +5.67% | 201B | |
| -10.14% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- LLY Stock
